SpringerLink
Log in

Endocardial Gene Delivery Using NOGA Catheter System

  • Protocol
  • First Online:
Cardiac Gene Therapy

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2573))

Abstract

NOGA/MyoStar system uses low magnetic fields and endomyocardial electrical parameters, allowing precise endomyocardial injections of therapeutic agents to ischemic yet viable myocardium which is most likely to respond to the treatment. Preclinical and clinical studies have shown that NOGA/MyoStar guided intramyocardial injections are safe, feasible and a minimally invasive way to deliver gene therapy to the heart. Here we describe how to perform electroanatomical map** and injections to hibernating myocardium in the preclinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. James SL, Abate D, Abate KH et al (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789–1858. https://doi.org/10.1016/S0140-6736(18)32279-7

    Article  Google Scholar 

  2. Neumann FJ, Sechtem U, Banning AP et al (2020) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41:407–477

    Article  Google Scholar 

  3. Kieserman JM, Myers VD, Dubey P et al (2019) Current landscape of heart failure gene therapy. J Am Heart Assoc 8. https://doi.org/10.1161/JAHA.119.012239

  4. Psaltis PJ, Worthley SG (2009) Endoventricular electromechanical map**-the diagnostic and therapeutic utility of the NOGA XP Cardiac Navigation System. J Cardiovasc Transl Res 2:48–62. https://doi.org/10.1007/S12265-008-9080-7

    Article  Google Scholar 

  5. Duran JM, Taghavi S, Berretta RM et al (2012) A characterization and targeting of the infarct border zone in a swine model of myocardial infarction. Clin Transl Sci 5:416. https://doi.org/10.1111/J.1752-8062.2012.00432.X

    Article  CAS  Google Scholar 

  6. Yee K, Malliaras K, Kanazawa H et al (2014) Allogeneic Cardiospheres delivered via percutaneous Transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathy. PLoS One 9. https://doi.org/10.1371/JOURNAL.PONE.0113805

  7. Garbayo E, Gavira JJ, de Yebenes MG et al (2016) Catheter-based Intramyocardial injection of FGF1 or NRG1-loaded MPs improves cardiac function in a preclinical model of ischemia-reperfusion. Sci Rep 6. https://doi.org/10.1038/SREP25932

  8. Järveläinen N, Halonen P, Nurro J et al (2021) Citrate-saline formulated mRNA delivery into the heart muscle with an electromechanical map** and injection catheter does not lead to therapeutic effects in a porcine chronic myocardial ischemia model. Hum Gene Ther. https://doi.org/10.1089/HUM.2021.149

  9. Lähteenvuo JE, Lähteenvuo MT, Kivelä A et al (2009) Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation 119:845–856. https://doi.org/10.1161/CIRCULATIONAHA.108.816454

    Article  CAS  Google Scholar 

  10. Rutanen J, Rissanen TT, Markkanen JE et al (2004) Adenoviral catheter-mediated Intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 109:1029–1035. https://doi.org/10.1161/01.CIR.0000115519.03688.A2

    Article  CAS  Google Scholar 

  11. Vale PR, Losordo DW, Milliken CE et al (2001) Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical map** in patients with chronic myocardial ischemia. Circulation 103:2138–2143. https://doi.org/10.1161/01.CIR.103.17.2138

    Article  CAS  Google Scholar 

  12. Kastrup J, Jørgensen E, Rück A et al (2005) Direct intramyocardial plasmid vascular endothelial growth factor-a 165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study: the Euroinject one trial. J Am Coll Cardiol 45:982–988. https://doi.org/10.1016/j.jacc.2004.12.068

    Article  CAS  Google Scholar 

  13. Ripa RS, Wang Y, Jørgensen E et al (2006) Intramyocardial injection of vascular endothelial growth factor-a 165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 27:1785–1792. https://doi.org/10.1093/eurheartj/ehl117

    Article  CAS  Google Scholar 

  14. Fuchs S, Dib N, Cohen BM et al (2006) A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease. Catheter Cardiovasc Interv 68:372–378. https://doi.org/10.1002/CCD.20859

    Article  Google Scholar 

  15. Stewart DJ, Kutryk MJB, Fitchett D et al (2009) VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 17:1109–1115. https://doi.org/10.1038/mt.2009.70

    Article  CAS  Google Scholar 

  16. Kukuła K, Chojnowska L, Dabrowski M et al (2011) Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). Am Heart J 161:581–589. https://doi.org/10.1016/j.ahj.2010.11.023

    Article  CAS  Google Scholar 

  17. Hedman M, Hartikainen J, Syvänne M et al (2003) Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio angiogenesis trial (KAT). Circulation 107:2677–2683. https://doi.org/10.1161/01.cir.0000070540.80780.92

    Article  CAS  Google Scholar 

  18. Hartikainen J, Hassinen I, Hedman A et al (2017) Adenoviral intramyocardial VEGF-DDNDC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. Eur Heart J 38:2547–2555. https://doi.org/10.1093/eurheartj/ehx352

    Article  CAS  Google Scholar 

  19. Gyöngyösi M, Dib N (2011) Diagnostic and prognostic value of 3D NOGA map** in ischemic heart disease. Nat Rev Cardiol 8(7):393–404. https://doi.org/10.1038/nrcardio.2011.64

    Article  Google Scholar 

Download references

Acknowledgments

This study was supported by Finnish Academy Flagship grant.

Author information

Author notes

  1. Satu Siimes and Niko Järveläinen contributed equally to this manuscript.

Authors and Affiliations

  1. A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland

    Satu Siimes, Niko Järveläinen, Henna Korpela & Seppo Ylä-Herttuala

  2. Heart Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland

    Seppo Ylä-Herttuala

Authors
  1. Satu Siimes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niko Järveläinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henna Korpela
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seppo Ylä-Herttuala
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seppo Ylä-Herttuala .

Editor information

Editors and Affiliations

  1. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Kiyotake Ishikawa

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Siimes, S., Järveläinen, N., Korpela, H., Ylä-Herttuala, S. (2022). Endocardial Gene Delivery Using NOGA Catheter System. In: Ishikawa, K. (eds) Cardiac Gene Therapy. Methods in Molecular Biology, vol 2573. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2707-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-2707-5_14

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-2706-8

  • Online ISBN: 978-1-0716-2707-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation